Clin Lab. 2020 Dec 1;66(12). doi: 10.7754/Clin.Lab.2020.200324.
Diabetes mellitus is a chronic illness that is a worldwide issue. HbA1c has been used to monitor glycemic control in patients with diabetes for many years. Although HbA1c measurement is needed for calculating estimated average blood glucose (eAG), it is now recommended that eAG is used instead of HbA1c for expression of blood glucose control and communication with patients and health care providers. This study, investigated fasting blood glucose (FBS) as an indicator of overall chronic blood sugar control by assessing the correlation between FBS with eAG derived from HbA1c.
The blood samples for HbA1c assay were collected in EDTA tubes and were analyzed by an HPLC analyzer (G8 Tosoh, Japan). Blood samples for FBS were collected in serum separator tubes, transported, and centrifuged for 15 minutes at 3,000 g. FBS levels were determined in serum samples with the enzymatic hexokinase method by a clinical chemistry analyzer (Architect 8000, Abbott, USA).
Statistical analysis was performed on 1,740 patients with type 2 diabetes mellitus with HbA1c levels above 6.5 mmol/L. The difference between FBS (9.3 ± 3.7 mmol/L) and eAG (11.14 ± 2.7 mmol/L) was statistically signif-icant (p < 0.0001). The correlation coefficient between FBS and eAG was r = 0.65 (95% CI; 0.62 - 0.69), with a p-value < 0.0001. While the correlation coefficient between FBS and eAG at HbA1c < 6.5% was r = 0.251 (95% CI, 0.16 - 0.34), with a significant p-value of < 0.00001. The combined data, standard deviation (SD), median, and interquartile range of eAG and FBS for all of the diabetic groups (n = 2,315), were 10.1 ± 3.00 mmol/L, 9.5 mmol/L, and 7.75 - 12.03 mmol/L for eAG, respectively. Similarly, these values were 8.5 ± 3.6 mmol/L, 7.5 mmol/L, and 6.0 - 10.00 mmol/L for FBS, respectively.
We concluded that there is a moderate and significant positive correlation between fasting blood sugar and the estimated average blood glucose derived from HbA1c. Although FBS might be helpful for daily monitoring of diabetes. Further studies must be conducted to provide solid results to support that FBS and its derived variable eAG can replace HbA1c as an indicator of long-term overall control of T2DM patients.
糖尿病是一种全球性的慢性疾病。HbA1c 多年来一直被用于监测糖尿病患者的血糖控制情况。尽管需要 HbA1c 测量值来计算估计平均血糖 (eAG),但现在建议使用 eAG 代替 HbA1c 来表达血糖控制情况,并与患者和医疗保健提供者进行沟通。本研究通过评估 FBS 与 HbA1c 衍生的 eAG 之间的相关性,探讨了 FBS 作为整体慢性血糖控制的指标。
HbA1c 测定的血液样本采集于 EDTA 管中,并用 HPLC 分析仪 (G8 Tosoh, Japan) 进行分析。FBS 的血液样本采集于血清分离管中,运输后以 3000g 离心 15 分钟。用临床化学分析仪 (Architect 8000,Abbott,USA) 用酶法己糖激酶法测定血清样本中的 FBS 水平。
对 1740 例 HbA1c 水平大于 6.5mmol/L 的 2 型糖尿病患者进行了统计学分析。FBS(9.3 ± 3.7mmol/L)与 eAG(11.14 ± 2.7mmol/L)之间的差异具有统计学意义 (p < 0.0001)。FBS 与 eAG 之间的相关系数为 r = 0.65(95%CI: 0.62-0.69),p 值<0.0001。而当 HbA1c<6.5%时,FBS 与 eAG 之间的相关系数为 r = 0.251(95%CI,0.16-0.34),p 值<0.00001。对于所有糖尿病组(n=2315),eAG 和 FBS 的合并数据、标准差(SD)、中位数和四分位距分别为 10.1 ± 3.00mmol/L、9.5mmol/L 和 7.75-12.03mmol/L。同样,这些值分别为 8.5 ± 3.6mmol/L、7.5mmol/L 和 6.0-10.00mmol/L。
我们得出结论,FBS 与 HbA1c 衍生的 eAG 之间存在中度且显著的正相关关系。尽管 FBS 可能有助于糖尿病的日常监测。但需要进一步的研究来提供可靠的结果,以支持 FBS 和其衍生的 eAG 可以替代 HbA1c 作为 T2DM 患者长期整体控制的指标。